We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 588

ML Strategies Health Care Lame Duck Preview
  • Mintz
  • USA
  • November 2 2018

With the opioid bill passed, the House on recess and the Senate having cut a deal to get out the door, we all begin to wonder: after the dust settles

President Trump Signs Bipartisan Opioid Legislation into Law; Includes Open Payments Reporting Expansion
  • Reed Smith LLP
  • USA
  • October 24 2018

President Trump has just signed into law HR 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for

Taxation & Representation, September 25, 2018
  • Brownstein Hyatt Farber Schreck LLP
  • USA
  • September 25 2018

With the midterm elections just weeks away, both parties have been hitting the campaign trail hard, strutting their stuff to win over voters. Below

Senate Overwhelmingly Clears Bipartisan Opioid Package
  • Squire Patton Boggs
  • USA
  • September 24 2018

Nearly three months following House passage of a legislative proposal related to America’s opioid epidemic, the Senate overwhelmingly cleared its own

FDA Proposes New Rule to Increase Transparency and Access to Agency Documents Under FOIA
  • Hogan Lovells
  • USA
  • September 17 2018

The Food and Drug Administration (“FDA” or “the agency”) recently issued a proposed rule that will ease the Freedom of Information Act (“FOIA”)

Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • July 23 2018

This week’s “Capitol Hill Healthcare Update” includes the latest on a series of healthcare bills scheduled for House votes, including one to repeal

Serving the Legal Needs of Dietary Supplement Companies
  • Porzio Bromberg & Newman PC
  • USA
  • July 17 2018

A variety of legal and regulatory challenges exist in the dietary supplement industry, including federal and state legislatures, agencies and courts. Some recent significant developments are summarized below....

Seventh Circuit Upholds FDA’s Use of FOIA Exemptions to Refuse Disclosures to Plaintiff
  • Reed Smith LLP
  • USA
  • June 20 2018

On this date 46 years ago, President Nixon and his aides had a conversation about the Watergate break-in and cover-up. What did they say? We do not

Pharmaceuticals and Brexit: Keeping the industry healthy
  • Linklaters LLP
  • United Kingdom, European Union
  • June 19 2018

It is estimated that each month 37 million packs of medicines are supplied from European countries to the UK with 45 million heading in the other

The Weekly Hill Update
  • Baker & Hostetler LLP
  • USA
  • June 11 2018

Below is the Federal Policy team’s weekly preview published each Monday that Congress is in session...